The Doctors Company and ProAssurance
On March 19, 2025, ProAssurance (‘PRA’) announced they agreed to be acquired by The Doctors Company (‘TDC’) for $1.3 billion in cash. The transaction is not subject to a financing condition but to the approval by PRA’s stockholders and the receipt of regulatory approvals.
Time will tell us if this deal is actually a game changer for the MPL industry.
Here is what I have been thinking:
1- PRA is a public company. There can be another suitor. Who?
- Berkshire Hathaway/MedPro? They would have an even harder time with anti-trust regulators.
- Coverys? Technically possible with their surplus of $1.4 billion.
- A private equity fund? They hate to do hostile mid-cap deals but this is possible.
The stockholders won't push back with that stock price bump at $25 per share, a 60% premium compared to market price.
PRA has been available for the past 4-5 years. Their acquisition of NORCAL was intended to make them more attractive for a buyer. If someone else were seriously interested, Goldman Sachs (financial advisor to PRA) would already know. We'll see soon.
2- Anti-trust reaction
The acquisition may be under scrutiny from regulators in several states, where the combined concern is close to anti-trust thresholds: California, Nevada, Florida, Michigan, ...
The new giant may even need to sell parts of their books: an opportunity for others?
But the MPL market is notoriously fragmented nationwide with top 20 carriers accounting for only 60% market share. So, this deal should go through.
3- Integration
As for most larger M&A transactions, Integration will be the main challenge indeed, and it will be very long.
TDC has a strong track record of acquisitions integration, but PRA is not just another acquisition.
They can expect higher turnover with management and higher churn with policy holders: yet another opportunity for MPL insurance carriers.
4- Consequences on MPL market and competition
This major deal will trigger another round of consolidation.
Larger carriers with deeper pockets ($12 billion combined surplus for TDC/PRA) will only tease plaintiff bars and juries towards more mega verdicts.
It may also lead to firmer premiums, which is not bad for the market.
​
Eventually, the independent players will have an even more pressing need to enhance operational efficiency.
​
What other thoughts do you want to share?
​